LIGAND PHARMACEUTICALS INC【LGND】
| Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Royalties | - | - | - | - | - | - | - | 129 | 47 | 34 | 49 | 73 | 84 | 109 |
|---|
| Intangible Royalty Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 95 |
|---|
| Financial Royalty Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 13 |
|---|
| Captisol | - | - | - | - | - | - | - | 29 | 31 | 110 | 164 | 104 | 28 | 31 |
|---|
| Contract revenue and other income | - | - | - | - | - | - | - | - | - | - | - | - | - | 27 |
|---|
| Total revenues and other income | - | - | - | - | - | - | - | 251 | 120 | 186 | 277 | 196 | 131 | 167 |
|---|
| Cost of Captisol | - | - | - | - | - | - | - | - | 11 | 30 | 62 | 53 | 11 | 11 |
|---|
| Cost, Amortization | - | - | - | - | - | - | - | 16 | 17 | 23 | 47 | 34 | 34 | 33 |
|---|
| Research and development | 10 | 11 | 9 | 12 | 13 | 21 | 27 | 28 | 56 | 59 | 69 | 36 | 25 | 21 |
|---|
| General and administrative | 15 | 16 | 18 | 23 | 24 | 27 | 29 | 38 | 42 | 64 | 57 | 70 | 53 | 79 |
|---|
| Financial royalty assets impairment | - | - | - | - | - | - | - | - | - | - | - | - | - | 31 |
|---|
| Fair value adjustments to partner program derivatives | - | - | - | - | - | - | - | - | - | - | - | - | - | -15 |
|---|
| Total operating costs and expenses | 32 | 31 | 34 | 45 | 45 | 65 | 73 | 88 | 126 | 178 | 198 | 193 | 121 | 190 |
|---|
| Gain on sale of Pelican | - | - | - | - | - | - | - | - | - | 17 | - | - | 2 | - |
|---|
| Operating income (loss) from continuing operations | -1 | 1 | 15 | 20 | 27 | 44 | 68 | 164 | 807 | 26 | 79 | 3 | 12 | -23 |
|---|
| Gain (Loss) on Investments | - | - | - | - | - | - | - | - | 3 | -17 | -4 | 29 | 46 | 75 |
|---|
| Interest income | 0 | - | - | - | - | - | - | - | 28 | 8 | 1 | 2 | 8 | 8 |
|---|
| Interest expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 |
|---|
| Other Nonoperating Income (Expense) | 1 | 1 | -0 | 2 | 2 | 3 | 5 | -6 | -6 | -0 | -9 | 4 | -2 | -55 |
|---|
| Total non-operating income, net | -2 | -4 | -6 | -8 | 8 | -36 | -11 | 10 | -10 | -36 | -32 | 33 | 52 | 25 |
|---|
| Income before income tax from continuing operations | - | - | - | - | - | - | - | - | - | - | 47 | 36 | 64 | 3 |
|---|
| Income tax expense | -13 | - | 0 | 0 | -220 | 10 | 45 | 30 | 167 | -8 | -10 | 41 | 10 | 7 |
|---|
| Net income (loss) from continuing operations | 10 | -3 | 9 | 12 | 257 | - | - | - | - | - | - | -5 | 54 | -4 |
|---|
| Net loss from discontinued operations | - | - | - | - | - | - | - | - | - | - | - | -28 | -2 | - |
|---|
| Net income (loss): | 10 | -1 | 11 | 12 | 257 | -2 | 13 | 143 | 629 | -3 | 57 | -33 | 52 | -4 |
|---|
| Income (Loss) from Continuing Operations, Per Basic Share | - | - | 0.43 | 0.59 | 13 | -0.11 | 0.6 | 6.77 | - | - | - | -0.31 | 3.11 | -0.22 |
|---|
| Basic net loss from discontinued operations (in USD per share) | - | - | 0.13 | - | - | 0.04 | - | - | - | - | - | -1.67 | -0.1 | - |
|---|
| Basic net income (loss) per share (in USD per share) | - | - | 0.56 | 0.59 | 13 | -0.08 | 0.6 | 6.77 | 33.13 | -0.18 | 3.44 | -1.98 | 3.02 | -0.22 |
|---|
| Income (Loss) from Continuing Operations, Per Diluted Share | - | - | 0.43 | 0.56 | 12.12 | -0.11 | 0.53 | 5.96 | - | - | - | -0.31 | 3.03 | -0.22 |
|---|
| Diluted net loss from discontinued operations (in USD per share) | - | - | 0.12 | - | - | 0.04 | - | - | - | - | - | -1.67 | -0.09 | - |
|---|
| Diluted net income (loss) per share (in USD per share) | - | - | 0.55 | 0.56 | 12.12 | -0.08 | 0.53 | 5.96 | 31.85 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 |
|---|